What Is Diphtheria?

Diphtheria is an acute bacterial infection caused by toxigenic strains of Corynebacterium diphtheriae. The bacteria produce a potent exotoxin that destroys tissue in the respiratory tract and can spread through the bloodstream to damage the heart, nerves, and kidneys. Although vaccines have made diphtheria rare in high-income countries, the World Health Organization (WHO) still reports thousands of cases annually in regions with low immunization coverage, particularly in parts of Asia, Africa, and South America. The disease was once a leading cause of childhood death worldwide, and it remains a serious threat in under-vaccinated communities and during humanitarian emergencies.

Transmission occurs primarily via respiratory droplets from coughing or sneezing. Incubation is typically two to five days, though it can extend to ten days. Infected individuals may be contagious for up to four weeks if untreated, and asymptomatic carriers can also spread the bacteria, making containment difficult without widespread vaccination.

Common Symptoms of Childhood Diphtheria

Recognizing diphtheria early is challenging because initial symptoms mimic those of viral upper respiratory infections. However, the progression to hallmark signs is rapid and distinct. Symptoms typically appear in stages, and awareness of this timeline helps parents and clinicians act decisively.

Early Stage (Days 1–3)

  • Sore throat and hoarseness — The earliest complaint, often dismissed as a cold. The throat appears red and mildly inflamed.
  • Low-grade fever — Usually below 102°F (39°C), accompanied by chills and malaise.
  • Fatigue and weakness — The child may seem more tired than usual, with reduced appetite and irritability.

Progressive Stage (Days 3–7)

  • Gray or white pseudomembrane — A thick, adherent coating forms on the tonsils, pharynx, or larynx. This membrane is a mix of dead cells, fibrin, and bacteria. Attempting to remove it causes bleeding and worsens airway obstruction.
  • Bull neck appearance — Swelling of the cervical lymph nodes and soft tissues gives the neck a pronounced, bull-like contour. This is a classic sign of severe diphtheria and indicates extensive toxin absorption.
  • Difficulty swallowing (dysphagia) — The child may drool or refuse to eat because of pain and obstruction.
  • Respiratory distress — Stridor (a high-pitched breathing sound), nasal flaring, and retractions indicate airway narrowing. This is a medical emergency.
  • Nasal diphtheria — In some cases, the infection is limited to the nasal cavity, producing a serosanguinous discharge that can erode the skin around the nostrils.

Advanced Stage (Beyond Day 7)

  • Systemic toxicity — The child appears profoundly ill, with pallor, rapid pulse, and low blood pressure.
  • Neurologic signs — Cranial nerve palsies can cause nasal speech, difficulty swallowing, and blurred vision. Peripheral neuropathy may develop weeks later.
  • Cardiac involvement — Myocarditis may present as chest pain, palpitations, or heart failure. It can occur suddenly and is often fatal.

Any child presenting with a sore throat and a gray membrane on the tonsils should be evaluated immediately for diphtheria. Early intervention directly reduces mortality and complication rates.

Risks and Complications

Diphtheria carries a case fatality rate of 5–10% even with treatment, and up to 20% among children under five years old. The diphtheria toxin is responsible for nearly all systemic damage. Complications can affect multiple organ systems and may appear days to weeks after the initial infection.

Cardiac Complications

Myocarditis occurs in 10–25% of diphtheria cases. The toxin disrupts myocardial cell function, leading to arrhythmias, heart block, and dilated cardiomyopathy. Electrocardiogram changes can develop around the second week of illness. Cardiac damage may be permanent and can cause sudden death even after the infection appears to be resolving.

Neurologic Complications

Peripheral neuropathy typically develops 2–8 weeks after onset. Early signs include palatal paralysis (nasal voice, regurgitation of fluids) and loss of accommodation (blurred vision). Progressive weakness can resemble Guillain-Barré syndrome. Most children eventually recover neurological function, but recovery may take months and some deficits persist.

Respiratory Complications

Airway obstruction from the pseudomembrane is the most immediate life-threatening risk. The membrane can occlude the larynx or trachea, requiring emergency intubation or tracheostomy. Secondary pneumonia from aspiration or bacterial superinfection is also common.

Renal and Hepatic Injury

Acute kidney injury and liver dysfunction can occur due to toxin-mediated cell damage and systemic hypotension. These complications increase the complexity of management and prolong hospitalization.

Risk Factors for Severe Disease

  • Unvaccinated or under-vaccinated status — The strongest predictor of severe diphtheria.
  • Age under 5 years — Immature immune systems and smaller airways heighten risk.
  • Delayed treatment — Every hour without antitoxin increases toxin burden.
  • Malnutrition and poverty — Overcrowded living conditions and poor healthcare access amplify transmission and delay care.

Survivors may face long-term sequelae, including chronic heart failure, persistent neuropathy, and reduced lung function. These outcomes underscore why prevention is far superior to treatment.

How Diphtheria Spreads

Understanding transmission dynamics is vital for containment. Diphtheria spreads through:

  • Respiratory droplets — Coughing, sneezing, or talking within close range (under 6 feet).
  • Direct contact — Touching contaminated surfaces or skin lesions (cutaneous diphtheria).
  • Asymptomatic carriers — Up to 5% of individuals in endemic areas carry C. diphtheriae without symptoms, unknowingly perpetuating transmission.

Crowded settings such as schools, daycare centers, refugee camps, and households with multiple generations facilitate rapid spread. The bacteria can survive on dry surfaces for weeks, though fomite transmission is less common than droplet spread.

Diagnosis and Testing

Clinical suspicion is the cornerstone of diphtheria diagnosis. Laboratory confirmation, while important, should never delay treatment. The diagnostic workup includes:

  • Throat culture — A swab from beneath the pseudomembrane is plated on selective media (e.g., tellurite agar). Growth of C. diphtheriae typically appears within 24–48 hours.
  • Gram stain — Shows gram-positive rods arranged in Chinese-character formation. This rapid test can support clinical suspicion but is not definitive.
  • PCR testing — Detects the diphtheria toxin gene (tox) directly, offering faster turnaround than culture. PCR is increasingly used in reference laboratories.
  • Antibiotic susceptibility testing — Guides antimicrobial selection, especially in areas with emerging resistance.
  • Serology — Antibody titers can assess immunity status but are not useful for acute diagnosis.

Differential diagnoses include streptococcal pharyngitis, infectious mononucleosis, Vincent angina, and other causes of membranous tonsillitis. Any child with a membranous throat infection and systemic toxicity should be isolated and treated for diphtheria until proven otherwise.

Treatment Approaches

Diphtheria treatment has three pillars: neutralization of toxin, elimination of bacteria, and supportive care. All three must proceed simultaneously and urgently.

Antitoxin Therapy

Equine diphtheria antitoxin is the only specific antidote. It neutralizes unbound toxin and must be administered as early as possible, ideally within 24 hours of symptom onset. Antitoxin does not reverse toxin already bound to cells, which explains the time sensitivity. Dosage depends on severity and ranges from 20,000 to 120,000 units intravenously. Skin testing for equine serum sensitivity is recommended due to the risk of anaphylaxis.

Antibiotic Therapy

Antibiotics stop bacterial replication and toxin production, and they reduce contagiousness. Recommended regimens include:

  • Erythromycin (oral or intravenous) for 14 days — First-line agent.
  • Azithromycin — Alternative for children intolerant of erythromycin.
  • Penicillin G or amoxicillin — Effective but less commonly used due to resistance concerns.

Antibiotics alone cannot treat established diphtheria; they only prevent further toxin production. Thus, antitoxin remains the most critical intervention. After completing therapy, two negative throat cultures are required before discontinuing isolation.

Supportive Care

  • Airway management — Intubation or tracheostomy if the pseudomembrane obstructs breathing. Emergency equipment must be at the bedside.
  • Cardiac monitoring — Continuous ECG for at least two weeks due to the risk of myocarditis. Serial echocardiograms may be needed.
  • Nutritional support — Nasogastric feeding if swallowing is impaired.
  • Respiratory support — Supplemental oxygen or mechanical ventilation for respiratory failure.
  • Neurologic monitoring — Assessment of cranial nerve function and strength. Physical therapy may be required during recovery.

Mortality is highest in the first week, primarily from airway obstruction and myocarditis. Survival beyond two weeks generally leads to full recovery, though some children face lifelong disability.

Preventive Measures

Vaccination is the most effective and cost-efficient way to prevent diphtheria. The WHO recommends a primary series of three doses of diphtheria-containing vaccine starting at six weeks of age, followed by booster doses throughout life.

Vaccine Types and Schedule

  • DTaP — Diphtheria, tetanus, and acellular pertussis vaccine for children under 7 years. Given at 2, 4, and 6 months, with boosters at 15–18 months and 4–6 years.
  • Tdap — Reduced-dose diphtheria and tetanus toxoids with acellular pertussis for adolescents and adults, given at age 11–12 years.
  • Td — Diphtheria and tetanus booster recommended every 10 years throughout adulthood.

The vaccines contain inactivated diphtheria toxoid, which stimulates antibody production against the toxin. They are safe and highly effective, with a efficacy of approximately 95% after the primary series. Mild side effects include soreness at the injection site, low-grade fever, and fussiness; serious adverse events are extremely rare.

Herd Immunity

To prevent outbreaks, community vaccination coverage must exceed 85–90%. When coverage drops — due to vaccine hesitancy, conflict, or supply chain disruptions — diphtheria resurges. Outbreaks in Venezuela (2016–2019), Yemen (2017–present), and Nigeria (2020s) illustrate how rapidly the disease returns when immunization gaps widen.

Post-Exposure Prophylaxis

Close contacts of a diphtheria case should receive:

  • A booster dose of diphtheria vaccine if their last dose was more than 5 years ago.
  • A 7-day course of erythromycin or a single dose of benzathine penicillin.
  • Throat cultures to screen for colonization.
  • Clinical monitoring for 10 days for any signs of respiratory illness.

Global Context and Outbreak Management

Diphtheria remains endemic in many parts of Sub-Saharan Africa, South Asia, and Southeast Asia. The WHO reported 16,651 confirmed diphtheria cases globally in 2022, though actual numbers are likely higher due to underreporting. Outbreaks are driven by:

  • Low routine immunization coverage — Many countries have DTP3 coverage below 80%, below the herd immunity threshold.
  • Humanitarian crises — Refugees and internally displaced populations are disproportionately affected. Overcrowding, malnutrition, and disrupted healthcare systems create perfect conditions for transmission.
  • Antimicrobial resistance — Erythromycin-resistant C. diphtheriae strains are emerging, complicating treatment protocols.
  • Limited antitoxin supply — Global reserves of diphtheria antitoxin are fragile, with few manufacturers producing it. Ensuring access in outbreak settings is a major logistical challenge.

For international travelers, vaccination is essential. The CDC travel recommendations advise a booster dose for anyone traveling to endemic areas. Healthcare workers and aid personnel deployed to outbreak zones should maintain up-to-date boosters.

Additional Precautions

Beyond vaccination, practical measures reduce transmission risk and protect vulnerable children.

Hygiene and Environmental Measures

  • Hand hygiene — Frequent handwashing with soap and water, especially after contact with a sick individual.
  • Cough etiquette — Cover mouth and nose with a tissue or elbow when coughing or sneezing.
  • Surface disinfection — Use bleach-based cleaners on high-touch surfaces. C. diphtheriae is susceptible to standard disinfectants.
  • Ventilation — Open windows and improve airflow in crowded indoor spaces.

Community and School Policies

  • Exclusion of sick children — Keep children with suspected diphtheria out of school until they have completed treatment and obtained negative cultures.
  • Notification to health departments — Diphtheria is a notifiable disease in most countries. Early reporting triggers contact tracing and outbreak response.
  • Education campaigns — Teach parents and teachers to recognize acute infectious respiratory symptoms and to seek timely care. Provide clear information on the safety and importance of vaccines.

Breastfeeding and Nutrition

Breastfeeding provides passive immunity during infancy and reduces the risk of severe infection. Malnourished children have weaker immune responses and are more susceptible to diphtheria and its complications. Nutritional support programs in endemic regions can mitigate this risk.

What To Do If You Suspect Diphtheria

Time is the most critical factor when diphtheria is suspected. Every parent, teacher, and caregiver should know the immediate steps to take.

Immediate Actions

  1. Call emergency services or go directly to the nearest hospital emergency room. Do not wait for an appointment with a primary care provider. Diphtheria can progress from mild symptoms to life-threatening airway obstruction within hours.
  2. Isolate the child — Place a surgical mask on the child if tolerated. Keep the child away from family members, especially infants and elderly individuals. If multiple children are present, cohort them separately.
  3. Do not try to remove the membrane — Attempting to scrape off the pseudomembrane causes bleeding, worsens obstruction, and can release more toxin into the bloodstream.
  4. Prepare a clear history — Inform emergency staff of the child’s vaccination status, recent exposure to sick contacts, and any travel history to endemic areas. This information guides diagnosis and isolation protocols.
  5. Do not give over-the-counter remedies — Cough suppressants and pain relievers do not treat diphtheria and can mask deteriorating respiratory status.

Emergency Signs Requiring Urgent Care

  • Stridor or noisy breathing at rest
  • Nasal flaring and chest retractions
  • Blue or pale discoloration of lips and skin (cyanosis)
  • Drooling and inability to swallow saliva
  • Altered consciousness (confusion, lethargy, or unresponsiveness)
  • Rapid pulse or irregular heartbeat

If any of these signs are present, the child may need emergency airway intervention, including intubation or tracheostomy, and immediate antitoxin administration.

Hospital Management

Once in medical care, the child will be placed in strict isolation. Treatment includes diphtheria antitoxin (after appropriate testing for hypersensitivity), antibiotics, and supportive care as described above. The hospital infection control team will initiate contact tracing and offer post-exposure prophylaxis to close contacts. Hospital stays typically last 2–3 weeks, and follow-up appointments with cardiology and neurology are essential for monitoring late-occurring complications.

Long-Term Follow-Up

Children who survive diphtheria require long-term monitoring due to the risk of delayed complications. Serial ECGs and echocardiograms are advised for at least six months after discharge because myocarditis can present insidiously. Neurologic assessments should continue for at least one year. Vaccination should still be given after recovery, as natural immunity is not always lifelong and booster doses are needed.

Conclusion

Childhood diphtheria is a preventable but life-threatening disease that demands vigilance and immediate action. The diphtheria toxin leaves no margin for delay — early recognition of symptoms, rapid administration of antitoxin and antibiotics, and isolation of infected children are the pillars of effective management. Yet treatment is always second best to prevention. Widespread vaccination with DTaP and Tdap vaccines, reinforced by booster doses throughout life, is the single most powerful tool to protect children and communities. Parents, healthcare professionals, and policymakers must work together to maintain high immunization coverage, strengthen public health surveillance, and ensure that access to antitoxin and antibiotics is never disrupted. With sustained commitment and education, the world can maintain the gains made against diphtheria and prevent future generations from suffering its devastating effects.

For more detailed information on vaccination schedules and outbreak updates, consult the CDC’s diphtheria vaccine recommendations and the WHO diphtheria fact sheet. If you are traveling to a region with ongoing diphtheria transmission, check the CDC travel health notices before departure. Staying informed and vaccinated is the best defense against this preventable killer.